6 November 2025 | 7:31PM EST Equity Research GLOBAL HEALTHCARE: PHARMACEUTICALS The Obesity Evolution: GLP-1 Pricing Deals Offer Significant Potential Volume Unlock; LLY Advantaged Today, Eli Lilly and Novo Nordisk announced drug pricing deals with the US government which across the portfolio largely echoed deals signed by Pfizer and AstraZeneca, but also included provisions to reduced GLP-1 prices to (1.) c.$350 per month on TrumpRx.com - trending to $245 over time (timeframe not confirmed but our interpre ...